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Abstract
Background: Human influenza virus isolates generally grow poorly in embryonated chicken eggs. Hence, gene
reassortment of influenza A wild type (wt) viruses is performed with a highly egg adapted donor virus, A/Puerto Rico/8/
1934 (PR8), to provide the high yield reassortant (HYR) viral ‘seeds’ for vaccine production. HYR must contain the
hemagglutinin (HA) and neuraminidase (NA) genes of wt virus and one to six ‘internal’ genes from PR8. Most studies of
influenza wt and HYRs have focused on the HA gene. The main objective of this study is the identification of the molecular
signature in all eight gene segments of influenza A HYR candidate vaccine seeds associated with high growth in ovo.
Methodology: The genomes of 14 wt parental viruses, 23 HYRs (5 H1N1; 2, 1976 H1N1-SOIV; 2, 2009 H1N1pdm; 2 H2N2 and
12 H3N2) and PR8 were sequenced using the high-throughput sequencing pipeline with big dye terminator chemistry.
Results: Silent and coding mutations were found in all internal genes derived from PR8 with the exception of the M gene.
The M gene derived from PR8 was invariant in all 23 HYRs underlining the critical role of PR8 M in high yield phenotype.
None of the wt virus derived internal genes had any silent change(s) except the PB1 gene in X-157. The highest number of
recurrent silent and coding mutations was found in NS. With respect to the surface antigens, the majority of HYRs had
coding mutations in HA; only 2 HYRs had coding mutations in NA.
Significance: In the era of application of reverse genetics to alter influenza A virus genomes, the mutations identified in the
HYR gene segments associated with high growth in ovo may be of great practical benefit to modify PR8 and/or wt virus
gene sequences for improved growth of vaccine ‘seed’ viruses.
Citation: Ramanunninair M, Le J, Onodera S, Fulvini AA, Pokorny BA, et al. (2013) Molecular Signature of High Yield (Growth) Influenza A Virus Reassortants
Prepared as Candidate Vaccine Seeds. PLoS ONE 8(6): e65955. doi:10.1371/journal.pone.0065955
Editor: Todd Davis, Centers for Disease Control and Prevention, United States of America
Received August 23, 2012; Accepted May 1, 2013; Published June 11, 2013
Copyright:  2013 Ramanunninair et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research support for preparation of the NYMC reassortants was provided by the International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA)–Influenza Vaccine Supply Task Force. This project has been funded in part with federal funds from the National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: doris_bucher@nymc.edu
Introduction
Influenza A viruses (IAV) are single stranded, negative sense
RNA viruses belonging to the family Orthomyxoviridae [1]. IAV have
genomes comprised of eight segments which encode thirteen
proteins [2–6]. IAV causes both seasonal epidemics and
infrequently pandemics as occurred in 1918, 1957, 1968, 1977
and 2009. IAV undergo antigenic drift in the HA and to a lesser
extent in the NA genes as a consequence of the high mutation
rates introduced into the genome by the viral polymerase complex
during replication [7,8]. As a result, frequent updates of the
influenza vaccine composition are necessary to ensure that the
antigenic properties are as closely matched as possible to the most
prevalent antigenic variants circulating in the population [9,10].
Vaccination is the primary method of influenza prevention and
control [11,12]. The first inactivated influenza virus vaccine was
produced in the 1940s using wild type (wt) virus [13]. Since wt
viruses generally grow to low titer in embryonated chicken eggs
and efficient vaccine production depends on a virus ‘seed’ with the
ability to grow to high titer, high yield reassortants (HYRs) were
developed for type A influenza vaccine production [14]. To date
the majority of IAV used for preparation of inactivated vaccines
have been HYRs [15,16].
Currently there are two techniques to generate HYRs or HGRs
(High Growth Reassortants); the ‘classical’ reassortment method
and the reverse genetics approach. In the classical method, HYRs
are generated by co-inoculation of two viruses in ovo, namely a wt
virus and a hy donor virus (A/Puerto Rico/8/1934 (PR8) or an
H3N2 HYR with six PR8 genes encoding the ‘internal’ proteins).
HYRs must contain genes for the two surface glycoproteins, HA
and NA, of the wt virus and one or more of the ‘internal’ genes
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from PR8 or its derivatives. The classical reassortment method is
based on the selection of HYRs from a potential pool of 254
reassortants (256 total progeny minus 2 parents) via negative
selection using antibodies and/or antisera against the hy donor
HA and NA; thus reducing the pool to 64 candidates [17,18].
Positive selection occurs naturally in the egg host with the highest
growing reassortant best adapted to growth in ovo, out-replicating
lower growing reassortants. HYR candidates are then cloned by
limiting dilution [14,15,18]. In the reverse genetics approach, a
reassortant virus with a predefined gene constellation (donor:wt) is
generated in mammalian cells using a plasmid system with no
negative selection process involved [19–23]. The reverse genetics
reassortants are generated to have a fixed gene constellation,
generally 6:2 [six internal genes derived from PR8 and the genes
for the two surface glycoproteins, HA (either native or modified)
and NA from the wt virus] [24].
Most genetic characterization studies of influenza wt and
reassortant viruses have focused on the importance of HA coding
changes [25–29]. Previous studies involving one or two HYRs
have shown that HYRs deriving one or more of the PR8 internal
genes grow better in eggs than the original low yielding wt virus
[30–37]. However, large scale sequence analysis of IAV HYRs
belonging to different subtypes has not been performed to study
the egg adaptive changes occurring in the internal genes derived
from PR8. As far as we know, this is the first large scale sequence
analysis of HYR candidate virus seeds used in seasonal and
pandemic vaccine production over decades.
Our laboratory at New York Medical College (NYMC)
specializes in producing HYR seed viruses for both seasonal and
pandemic influenza vaccines by the classical reassortment method.
Earlier, we reported the gene constellation analysis of a panel of
HYRs prepared as candidate vaccine viruses and demonstrated
that the gene ratio and gene constellation yielding a reassortant
with hy phenotype is dependent on the individual wt virus and its
interaction with the hy donor virus [36]. Also, the hy property of
the reassortants generally relies on the selection of pre-existing
variants with mutations favorable for improved growth in ovo
occurring in the genes for the surface glycoproteins and/or the
internal (non HA and non NA) proteins [38]. Hence, to identify
the mutations associated with hy characteristics in ovo, the
complete genomes of a total of 23 HYRs prepared as candidate
vaccine seeds between 1957 and 2009, from 14 different wt viruses
belonging to H1N1, 1976 H1N1-SOIV, 2009 H1N1pdm, H2N2
and H3N2 subtypes were sequenced and analyzed. The mutations
observed in this analysis will be of considerable interest to
influenza vaccine researchers and can be applied to modification
of the sequences of the wt virus and/or the hy donor virus, PR8,
during the development of influenza A vaccine candidate viruses
with improved growth properties in ovo.
Materials and Methods
HYRs, hy Donor, and wt Parent Viruses
HYRs designated with an X, for example, X-31b were
developed by E.D. Kilbourne and his associates; HYRs designated
as NYMC X- (for example, NYMC X-163, are from the
laboratory of D. Bucher (Table 1). The reassortants developed at
NYMC in the Bucher laboratory are called High Yield
Reassortants (HYR) continuing the original designation from
E.D. Kilbourne who developed the classical reassortment method
[14]. In the text all HYRs are mentioned as starting with X-.
The hy donor virus PR8 (H1N1 subtype) was used to generate
H3N2 HYRs. To develop the H1N1 HYRs, H3N2 hy reassortants
were used to have a clear antigenic distinction between wt (H1N1)
and donor surface glycoproteins (H3N2) to facilitate antibody
selection during reassortment. Hy H3N2 donor viruses included
X-31b (H3N2 HYR made between A/Aichi/2/1968xPR8 with 6
‘internal’ genes from PR8 and the HA and NA from A/Aichi/2/
1968) and NYMC X-157 (H3N2 HYR made between A/New
York/55/2004xPR8 with HA and NA from A/New York/55/
2004; X-157 was subsequently found to be a mixture of 6:2 and
5:3 viruses with PB1s derived from both parents). In the case of the
1976 swine influenza vaccine, PR8 was used to generate the 1976
H1N1-SOIV reassortants X-53 and X-53a.
The HYRs with more than one in the same series (for example,
X-163 series, X-171 series etc) are derived from independent co-
infection experiments performed in parallel using the same wt
viruses. A total of 38 viruses including 23 HYRs, 14 wt viruses and
the hy donor virus PR8 were sequenced and analyzed.
Viral RNA Isolation and RT-PCR Amplification of M Gene
The quality of the extracted RNA for sequencing purposes was
checked by amplifying the M gene of all 38 samples by RT-PCR.
Viral RNA was isolated from 280 ml of allantoic fluid using
QIAmpH Viral RNA Mini Kit (Qiagen Inc., Valencia, CA) per the
manufacturer’s recommendations. RNA preparations were stored
at 220uC until further use. RT-PCR was carried out using Takara
One Step RNA PCR Kit (Clontech, Mountain View, CA)
according to the manufacturer’s recommendations. The RT-
PCR reaction mixture and the thermal conditions used were as
previously published [36]. The reactions were performed on an
Eppendorf MastercyclerH. The amplified RT-PCR products were
visualized on a 2% agarose gel with ethidium bromide in Tris
Acetate EDTA buffer.
Influenza A Virus HYR Genome Sequencing
The complete genome sequencing of the 38 RNA preparations
was carried out at J. Craig Venter Institute (JCVI, Maryland,
USA) under the NIAID Influenza Genome Sequencing Project
(NIGSP). Whole-genome sequencing of isolates was performed
using the high-throughput sequencing pipeline. The protocol was
as follows. Briefly described, an M13 sequence tag was added to
the 59 end of each degenerate primer used for RT-PCR. Primers
were designed to produce approximately 500-nucleotide (nt)
overlapping amplicons and provide 2X coverage of each genomic
segment. Each amplicon pair overlaps with its neighboring
amplicon by approximately 100 nt. Additionally a second set of
primers was designed to produce 500-nt amplicons offset by about
250 nt from the original primer pair, providing at least 4X
sequence coverage of each segment. Primers were arranged in a
96-well plate format; all RT-PCRs for each sample were
performed in one plate. Genomic RNA was amplified directly
by RT-PCR and sequenced. Ninety-six RT-PCRs reactions were
performed per RNA sample using a One-Step RT-PCR kit
(Qiagen Inc., Valencia, CA). Sequencing reactions were per-
formed using Big Dye Terminator chemistry (Applied Biosystems,
Carlsbad, CA) with 2 ml of template cDNA. Each amplicon was
sequenced from each end using M13 primers, and sequencing
reactions were analyzed on a 3730 ABI sequencer (Applied
Biosystems, Carlsbad, CA).
Genome Analysis
The sequences as determined for our laboratory PR8 internal
gene sequences had nucleotides missing at both ends. Therefore,
the PR8 gene sequences were compared with the PR8 sequences
from Schickli et al [39], to obtain the numbering for the full length
gene segments to permit alignment and analysis. H1 numbering is
used for the changes in HYRs deriving the internal genes from
Molecular Signature of Influenza A Vaccine Seeds
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PR8 [39]. The numbering for changes in the HYR’s HA, NA and
the internal genes derived from the wt viruses are according to the
subtype of the wt viruses [29,40]. The sequences were aligned
using the CLUSTAL W algorithm [41]. The nucleotide and
amino acid (aa) substitutions and sequence homology were
determined and analyzed using the MegAlignH module of the
DNASTAR package (DNASTAR, Inc., Madison, USA).
GenBank Accession Numbers
The complete genome sequence of all 23 HYRs, 14 wt viruses
and PR8 were submitted to GenBank via JCVI. The GenBank
accession numbers of influenza A wt viruses and HYRs analyzed
in this study are given as supporting information (Table S1). The
sequences for the HA and NA of wt virus AC/68 (HA gene:
AB295605; NA gene: AB295606) and wt virus UY/07 (HA gene:
EU716426 and NA gene: EU716427) were used from publicly
available GenBank sequences. The PB1, HA and NA sequences of
2009 H1N1pdm wt virus CA/2009 were used from published data
[42].
Statistical Analysis
Statistical significance of the nucleotide changes in terms of fold
increase in HA titer was analyzed using Student’s t-test. A value of
p,0.05 was considered statistically significant.
Results
Gene Constellation of HYRs
All HYRs mentioned in this study were generated by classical
reassortment in ovo. The frequency of origin of ‘internal’ genes in
the HYRs is shown in Fig. 1. Apart from PR8 internal genes, all
the H3N2 internal gene segments (except H3N2 M gene) were
incorporated at least once among the 23 HYRs. Among the
‘desired’ gene constellations associated with high growth (6:2 or
5:3), 43% of the vaccine seeds (10/23) contained 6:2 and 27% (6/
23) contained 5:3 gene compositions. Three HYRs had 4:4; two
had 3:5; one had 2:6 and one had 1:7 gene compositions. Thirteen
vaccine seeds acquired the complete polymerase complex from the
same parental virus (PR8-44% and wt-13%). 18/23 HYRs (78%)
derived both PB2 and PA from PR8. Among the wt derived genes,
Table 1. Influenza A virus HYRs analyzed in this study.
HYRS WT Virus WT abbreviation in text
H1N1 (X-31b-hy donor for X-113 and X-127; NYMC X-157-hy donor for X-163’s)
X-113a A/Texas/36/1991 TX/91
X-127a,b A/Beijing/262/1995 BJ/95
NYMC X-163 A/St. Petersburg/8/2006 SP/06
NYMC X-163A A/St. Petersburg/8/2006 SP/06
NYMC X-163B A/St. Petersburg/8/2006 SP/06
H1N1-SOIVc (PR8-hy donor X-539s; NYMC X-157-hy donor for X-179’s)
X-53a,d A/New Jersey/11/1976 NJ/76
X-53aa,d A/New Jersey/11/1976 NJ/76
NYMC X-179 A/California/07/2009 CA/2009
NYMC X-179Ad A/California/07/2009 CA/2009
H2N2 (PR8-hy donor)
X-135a,e A/Japan/305/1957 JP/57




NYMC X-149C6 A/Wyoming/03/2003 WY/03
NYMC X-157b A/New York/55/2004 NY/04
NYMC X-157A A/New York/55/2004 NY/04
NYMC X-157B A/New York/55/2004 NY/04
NYMC X-161b A/Wisconsin/67/2005 WI/05
NYMC X-161Bb A/Wisconsin/67/2005 WI/05
NYMC X-171 A/Brisbane/10/2007 BR/07
NYMC X-171A A/Brisbane/10/2007 BR/07
NYMC X-171B A/Brisbane/10/2007 BR/07
NYMC X-175Cb A/Uruguay/716/2007 UY/07
aHYRs prepared in E.D. Kilbourne laboratory, others at Bucher laboratory at NYMC.
bUsed in seasonal influenza vaccine production.
cSOIV- swine origin influenza virus.
dX-53 and X-53a were used in the 1976 swine influenza vaccine production and X-179A was used in the 2009 H1N1pdm vaccine production.
eX-135 was developed as a pre-pandemic vaccine seed candidate in the event of a reappearance of an H2N2 subtype in the population.
doi:10.1371/journal.pone.0065955.t001
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the wt NP was accompanied with at least one of the polymerase
subunits from wt virus in 5/23 (22%). The gene compositions and
the number of mutations is given in Table 2. The silent and coding
changes in H1N1, 1976 H1N1-SOIV, 2009 H1N1pdm and
H2N2 HYRs are given in Table 3 and Fig. 2. Silent and coding
changes in H3N2 HYRs are presented in Table 4 and Fig. 2. The
number of recurrent silent and coding changes per gene per
parental origin is shown in Fig. 3.
H1N1 HYRs ‘Internal’ Gene Sequences
H1N1 HYRs were generated using an H3N2 hy donor virus,
either X-31b or X-157 for delivery of PR8 internal genes during
reassortment of HYRs (Table 1). (Note: Although the original
analysis of X-157 gene composition by RT-PCR/RFLP analysis
showed that all six internal genes were derived from PR8,
subsequent sequence analysis at JCVI found that X-157 was a
mixture of two populations of HYRs, one with PR8 PB1 and a
second with NY/04 PB1. However all reassortants made with the
X-157 donor received PR8 PB1; none obtained the NY/04 PB1
gene).
PB2 gene. Among the five H1N1 HYRs, four derived the
PB2 gene from PR8 of which only X-127 had a single silent nt
change, A49C. X-113 derived PB2 from its TX/91 parent and
had no change.
PB1 gene. Four of the five H1N1 HYRs derived the PB1
gene from PR8. X-163B had a silent nt change, A1968G. Coding
changes were seen in X-113, Asn52Ser and in X-163, Ala734Thr.
X-127 derived PB1 from its parent, BJ/95, and had no changes.
PA gene. All five HYRs derived PA from PR8. A single
coding change Glu405Lys was found only in X-163.
NP gene. Four out of five of the H1N1 HYRs derived the NP
gene from PR8. The three X-163 HYRs had a recurrent coding
change, Ile131Met; X-127 had no change. X-113 deriving the NP
gene from its TX/91 parent had two coding changes, Pro35Gln
and Thr324Asn.
M gene. All five H1N1 HYRs derived the M gene from PR8
and had no changes.
NS gene. All five HYRs derived the NS gene from PR8. Both
X-113 and X-127 had recurrent silent changes, C147T and
G549A and a recurrent coding change Glu55Lys in NS1 and a
recurrent coding change Gly26Glu in NS2. No changes to NS
gene were seen in the X-163 series.
H1N1 Swine Origin HYRs ‘Internal’ Gene Sequences
All four swine origin H1N1-SOIV HYRs had 5:3 gene
compositions with PB1, HA and NA from wt virus. X-53 and
X-53a derived the remaining five genes from PR8 and the 2009
H1N1pdm reassortants X-179 and X-179A derived the remaining
five genes from X-157.
PB2 gene. All four HYRs had PR8 PB2. Both X-53 and X-
53a had the same silent nt change, A49C; no silent changes were
seen in X-179 or X-179A. No coding changes were found in the
PB2 gene for any of the four SOIV HYRs.
PB1 gene. All four H1N1-SOIV HYRs had wt PB1. X-53a
had a coding change, His576Tyr.
PA gene. All four HYRs had PR8 PA. Both X-53 and X-53a
had the same silent change, A1410G, with X-53a containing an
additional silent change, G2052T. For the two vaccine seeds (X-
179 and X-179A) developed for 2009 H1N1pdm, no silent
changes were seen; X-179 had two coding changes in PA,
Gln564Leu and Glu621Lys.
NP gene. All four HYRs obtained the PR8 NP gene. X-179A
had the coding change, Ile131Met; this change was also found in
the H1N1 X-163 series (Table 3).
M gene. No nt changes were seen in the PR8 derived M gene
for any of the four H1N1-SOIV HYRs.
NS gene. All four HYRs derived the NS gene from PR8. Both
X-53 and X-53a had the recurrent silent change, T144C in NS1
(Table 5 and 6). X-179 had a silent change C154T and X-179A
had four silent changes, G312C, G338C, A359G and G394A in
NS1.
H2N2 HYRs ‘Internal’ Gene Sequences
Two H2N2 HYRs were developed using hy donor virus PR8
(Table 1). PR8xKO/68 is a 3:5 HYR deriving PA, M and NS
genes from PR8 with the remaining five genes from wt virus KO/
68. X-135 is a 4:4 HYR deriving PB2, PA, M and NS genes from
PR8 with the remaining 4 genes from wt virus JP/57.
PB2 gene. X-135 had a silent change C1540A in PR8 PB2
gene. No change was seen in wt PB2 gene of PR8xKO/68 HYR.
PB1 gene. Both H2N2 HYRs derived wt PB1 and had no
change.
PA gene. Both H2N2 HYRs derived PR8 PA; PR8xKO/68
HYR had a silent change A1218T; X-135 had a coding change,
Asn578Asp.
Figure 1. Frequency of origin of ‘internal’ genes in HYRs in the present study.
doi:10.1371/journal.pone.0065955.g001
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NP gene. Both H2N2 HYRs had wt NP gene; only
PR8xKO/68 had a coding change, Tyr76Cys.
M gene. No silent or coding changes were found in M genes
for either HYR.
NS gene. Both HYRs derived PR8 NS. X-135 had three
silent changes A123G, C147T and G549A and a coding change
Glu55Lys in NS1. In addition X-135 also had a coding change
Gly26Glu in NS2. PR8xKO/68 had no changes.
Figure 2. Total number of nucleotide changes in HYRs. Total Changes: The majority of the nucleotide changes (Silent and Coding, black bars)
in the internal genes was found in the NS gene followed by PB1, PB2, NP, and PA. The HA gene had a total of 33 nucleotide changes; in contrast NA
had only 2 nucleotide changes, both coding changes. M gene had no nucleotide change in any of the 23 HYRs. Silent Changes: Silent nucleotide
changes were found in the internal genes of the HYR derived from hy donor virus, PR8 (blue bars). No silent changes were found in the internal genes
derived from wt viruses except in NYMC X-157 PB1 derived from wt virus NY/04 which had 13 silent changes. HA had 3 silent nucleotide changes
(green bar). NA and M genes had no silent changes in any of the 23 HYRs. Coding Changes: Among the internal proteins, the majority of the coding
changes (orange bars) were found in PR8 derived NS (14 total; 7 in NS1 and 7 in NS2), followed by PB1 (10 total; 7 in PB1 and 3 in PB1-F2), NP (9) and
PA (8). PB2 had only 1 coding change in contrast with 20 silent changes. M had no coding changes in any of the 23 HYRs. HA had 30 coding changes;
in contrast NA had only 2 coding changes (red bars).
doi:10.1371/journal.pone.0065955.g002
Figure 3. Total number of recurrent silent and recurrent coding changes in HYRs. The majority of PR8 derived recurrent silent changes are
found in NS1 (22) followed by PB2, NP, PB1-F2, and PA. The majority of the PR8 derived recurrent coding changes are found in NS2 followed by NS1,
NP, PB1-F2 and PB1. HA had a total of 17 recurrent coding changes involving more than one amino acid position (Table 9). NA and M genes had no
recurrent changes.
doi:10.1371/journal.pone.0065955.g003
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H3N2 HYRs ‘Internal’ Gene Sequences
Twelve H3N2 HYRs were sequenced and compared with
parental sequences; all were generated using the H1N1 hy donor
virus PR8 (Table 1).
PB2 gene. Nine H3N2 HYRs obtained the PB2 gene from
PR8. Of which, seven HYRs had silent changes, including a
recurrent silent change, A49C in X-31b, X-117 and X-157;
C1827T in X-157A, X171A, X-171B, and A2025G in X-157A
and X171A. Non-recurrent changes include, G594A, G1128A,
G1950A, C2073T and G2307A (X-171B), G1056A and A1953G
(X-117), C1068A (X-157B) (Table 4). A coding change was found
in the PB2 gene for X-157B, Pro121Ser. No changes were seen in
the three HYRs with wt PB2, X-149C6, X-161 and X-171.
PB1 gene. The PR8 derived PB1 for X-157 had a single silent
change G243T, while the PB1 gene derived from wt virus (NY/04)
for X-157 was found to have 13 silent changes (Table 4). Six
H3N2 HYRs obtained the PR8 PB1. Silent changes were seen in
X-157B, (T2058C) and in X-171B (C400A). Four HYRs had
coding changes including, Glu59Lys in X-117, Val690Ile in X-
161B and X-171B and Val344Ile in X-175C. Two coding
changes, Leu584Ile and Gln629Arg were found in the WT
derived X-157 PB1 gene. No changes were found in the remaining
five HYRs with wt PB1.
PA gene. Nine of the 12 H3N2 HYRs had the PR8 PA gene.
A silent change, G1504A was seen in the PR8 PA gene of X-157A.
A total of four coding changes were found in the PR8 PA; one in
X-157B (Val334Ile) and three in X-175C (Arg200Cys, Asp302Gly
and Lys386Arg). The remaining HYRs had no changes in the PA
gene regardless of parental origin (Table 2).
Table 2. Gene composition and number of silent and coding changes per gene in HYRs.
Subtype HYRs Gene Composition
(Gene Ratio) No. of Silent Changes (No. of Coding Changes)
(PR8:WT) PB2 PB1 PA HA NP NA M NS
H1N1
X-113 (4:4) 0a 0(1)b 0 0(1) 0(2) 0 0 2(2)
X-127 (5:3) 1 0 0 0(2) 0 0 0 2(2)
X-163 (6:2) 0 0(2)c 0(1) 0 0(1) 0 0 0
X-163A (6:2) 0 0(1)c 0 0 0(1) 0 0 0
X-163B (6:2) 0 1(1)c 0 0 0(1) 0 0 0
H1N1-SOIV/2009 H1N1pdm
X-53 (5:3) 1 0d 1 1(2) 0 0 0 1
X-53a (5:3) 1 0(1) 2 0(1) 0 0 0 1
X-179 (5:3) 0 0 0(2) 0(4) 0 0 0 1
X-179A (5:3) 0 0 0 0(3) 0(1) 0 0 4
H2N2
X-135 (4:4) 1 0 0(1) 0(1) 0 0 0 3(2)
PR8xKO/68 (3:5) 0 0 1 0(1) 0(1) 0 0 0
H3N2
X-31b (6:2) 1 0 0 0(2) 0 0 0 2(2)
X-117 (6:2) 3 0(1) 0 0 3 0 0 2(1)
X-149C6 (3:5) 0 0 0 0 3 0 0 2(2)
X-157 (6:2/5:3)e 1 A/A 0 0(1) 0 0 0 1
X-157A (5:3) 2 0 1 0(1) 0 0 0 1
X-157B (6:2) 1(1) 1 0(1) 0(2) 3 0 0 1
X-161 (1:7) 0 0 0 0 0 0 0 0
X-161B (6:2) 0 0(1) 0 0 0 0 0 1
X-171 (2:6) 0 0 0 0(3) 0(1) 0 0 2(3)
X-171A (4:4) 2 0 0 2(2) 0 0(1) 0 0
X-171B (6:2) 6 1(1) 0 0(3) 0 0 0 1
X-175C (6:2) 0 0(1) 0(3) 0(1) 0(1) 0(1) 0 1
Total genes (242) 29 33 27 37 29 37 24 26
aGenes derived from respective wt viruses are given in italics.
bBlack bold font are genes derived from the hy donor virus PR8.
cIncludes the coding change Cys42Phe in the PB1-F2 of the X-163 series of HYRs.
dRT-PCR/RFLP analysis showed X-53 PB1 derived from NJ/76 [36], however sequence data showed X-53 PB1 is a mixture of both PR8 and NJ/76 PB1 genes and also had
more numbers of ambiguities, hence not included in the analysis.
eNYMC X-157 PB1was a mixture of both PR8 and NY/04 PB1 genes.
A/A- PB1 is a mixture of PR8 and NY/04; A (PR8 PB1) had only one silent change, A (NY/04 PB1) had 13 silent and 2 coding changes.
doi:10.1371/journal.pone.0065955.t002
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NP gene. Ten HYRs obtained the PR8 NP gene. Three
HYRs with PR8 NP had silent changes, X-149C6 and X-157B
had the same changes, G210A, C369T and G924A. X-117 had
three silent changes, C369T, C426T and G924A. These recurrent
silent changes are not found in HYRs of other subtypes. Coding
changes, Gly117Arg and Lys46Glu, were seen in X-171 and X-
175C, respectively. No changes were found in seven H3N2 HYRs
whether the NP gene was derived from PR8 or wt.
M gene. No silent or coding changes were found for the PR8
derived M gene in any of the 12 H3N2 HYRs.
NS gene. Ten H3N2 HYRs contained the PR8 NS gene and
each had at least one change. Six HYRs, X-157, X-157A, X-
157B, X-161B, X-171B and X-175C had a recurrent silent
Table 3. Total nucleotide changes in H1N1 and H2N2 HYRs.





NS C147T, G549A; G163A(E55K), G77A(G26E)
X-127 PB2 A49C
HA A604G(R202G), A608T(D203V)




















X-179 PA A1691T(Q564L), G1861A(E621K)
HA G464A(G155E), A626C(K209T), G/D222D, A668G(Q223R)
NS C154T
X-179A HA A626C(K209T), G/D222D, A668G(Q223R)
NP A393G(I131M)









Silent changes are in regular font; Coding changes are in bold font with corresponding aa changes in the parentheses.
doi:10.1371/journal.pone.0065955.t003
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change, T144C in NS1. Another group of four HYRs, X-31b, X-
117, X-149C6 and X-171 had recurrent silent changes C147T
and G549A in NS1 and a recurrent coding change Gly26Glu in
NS2 (Table 7 and 8). From this group, except X-117, the other
three HYRs, X-31b, X-149C6 and X-171 had a recurrent coding
change, Glu55Lys in NS1. In addition, X-171 had another coding
change Leu77Phe in NS1. No changes were seen in the two HYRs
with the wt NS gene.
PB1-F2 Region of PB1
A total of 10 HYRs derived PB1 from PR8 and retained the 87
aa long PB1-F2. The HIN1 HYR, X-127 with BJ/95 PB1 had a
truncated 57aa long PB1-F2. The H1N1 SOIV HYRs, X-53a had
truncated 52 aa long PB1-F2; X-179 and X-179A had a truncated
PB1-F2 at 12 aa. The H2N2 HYRs (X-135 and PR8xKO/68) and
five out of 12 H3N2 HYRs (X-149C6, X-157A, X-161, X-171 and
X-171A) with wt derived PB1 had a PB1-F2 protein size of 90 aa.
X-157 which was a mixture had PB1 from both PR8 and wt
viruses (see earlier comment, see Note: Section B) had PB1-F2
proteins of 87 and 90 aa, respectively. The HYRs deriving PB1
(encoding PB1-F2) from PR8 (except X-117 and X-163 series) had
a single recurrent silent nt change, A57G. Whereas, the X-163
series of HYRs had a recurrent coding change, Cys42Phe, which is
the only coding change in the PB1 gene associated with PB1-F2.
HA Gene Sequences
The HYR seed viruses must derive HA and NA genes from
their respective wt viruses. Among the HYRs analyzed, three silent
changes and 30 coding changes were found in the HA genes
(Tables 2, 3 and 4).
H1N1. A silent nt change was found in X-53 (G525A). X-53
and X-127, each had two coding changes in the HA; Glu153Lys
and Ala178Thr (X-53), and Arg202Gly and Asp203Val (X-127).
X-113 had a single coding change, Gly239Asp. X-53a had a
coding change, Gly155Glu which was also found in X-179 (a 2009
H1N1pdm HYR). In addition, X-179 and X-179A shared three
coding changes, Lys209Thr, Gly/Asp222Asp and Gln223Arg.
H2N2. The Lys209Thr change seen in X-179 and X-179A
was also found in an H2N2 HYR (PR8xKO/68) (Table 9).
H3N2. X-171A had two silent nt changes, C54T and A198G.
Coding changes were found in the X-157 series of HYRs including
the same recurrent coding change, Ser219Tyr which was also
found in X-171B (Table 9). X-157B had a coding change,
Val66Phe. Both X-171 and X-171B had the coding change,
Gly186Val, together with an alanine deletion at position 198. X-
171A had a coding change, Leu194Pro. The H3N2 vaccine virus,
X-175C, had a single coding change Arg142Gly.
HA2 region. Four coding changes were found in the HA2
region, Lys401Asn (X-135, H2N2); Arg487Thr and Val510Gly
(X-31b, H3N2) and Asp489Asn (X-171A, H3N2) in the amino
terminus of the HA2. These changes are unique to this study.
HA coding changes and structure. Some of the coding
changes including Gly155Glu, Gly186Val, Leu194Pro,
Lys209Thr, Ser219Tyr, Gly/Asp222Asp and Gln223Arg, had
been reported earlier to affect receptor specificity and egg
adaptation [26–29,43–45]. The coding changes found in the
H3N2 HYRs are depicted in the structural model of an H3N2 HA
generated by PyMOL Molecular Graphics System (www.pymol.
org) (Fig. 4).
NA Gene Sequences
In our study, no silent nt changes were found in the NA gene for
any of the 23 HYRs. In contrast to HA with 31 coding changes,
only two HYRs had coding changes in the NA genes, both were
Table 4. Total nucleotide changes in H3N2 HYRs.
HYRs Gene Observed Nucleotide Changes
X-31b PB2 A49C
HA G1460C(R487T), T1529G(V510G)
NS C147T, G549A; G163A(E55K), G77A(G26E)
X-117 PB2 A49C, G1056A, A1953G
PB1 G175A(E59K)
NP C369T, C426T, G924A
NS C147T, G549A; G77A(G26E)
X-149C6 NP G210A, C369T, G924A
NS C147T, G549A; G163A(E55K), G77A(G26E)
X-157 PB2 A49C
PB1a G243T
PB1b A600G, T675C, T726C, C837T, A861G, T912A, T1728C,
















X-171 HA G557T(G186V), 594GACdeletion(A198),
T677G(I226S)
NP G349A(G117R)
NS C147T, G549A; G163A(E55K), C229T(L77F),
G77A(G26E)
X-171A PB2 C1827T, A2025G
HA C54T, A198G; T581C(L194P), G1465A(D489N)
NA A91G(T31A)











Silent changes are in regular font; Coding changes are in bold font with
corresponding aa.
changes in the parentheses.
X-157 was a mixture of two populations of HYRs, one with a PR8 PB1 and a
second with b NY/04 PB1.
doi:10.1371/journal.pone.0065955.t004
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N2 subtype, Thr31Ala in X-171A (H3N2) and Thr32Ile in X-
175C (H3N2). Both are located in the amino terminal end which
anchors NA in the viral envelope.
Codon Usage in HYR ‘Internal’ Genes of PR8 Origin
Both recurrent and individual silent changes were observed in
all the internal genes of the HYRs derived from PR8 except the M
gene. The A49C change found in the PB2 gene of six HYRs
(Table 5 and 6) is at the first codon of the arginine residue. Apart
from this recurrent change, the PB2 genes of five other HYRs had
a total of 14 silent nt changes (five G-A, four C-T, three A-G and
two C-A conversions). In the PB1 gene, the 17 silent changes
included five A-G, four T-C, three C-T, two G-A, one G-T, one
C-A and a T-A conversion. The seven silent nt changes in the
PB1-F2 gene are A-G conversions at the third codon of a
glutamine residue. In PA, four HYRs had silent changes, two A-G,
followed by a single conversion of G-A, G-T or A-T. The HA gene
had three silent changes (one G-A, one A-G and one C-T
Table 5. Recurrent silent nucleotide changes in HYRs.
Gene Change No. of HYRs Recurrent silent changes (all PR8 origin)
PB2 A49C 6 X-31b, X-53, X-53a, X-117, X-127, X-157
C1827T 3 X-157A, X-171A, X-171B
A2025G 2 X-157A, X-171A
PB1-F2 A57G 7 X-31b, X-113, X-157, X-157B, X-161B, X-171B, X-175C
PA A1410G 2 X-53, X-53a
NP G210A 2 X-149C6, X-157B
C369T 3 X-117, X-149C6, X-157B
G924A 3 X-117, X-149C6, X-157B
NS1 T144C 8 X-53, X-53a, X-157, X-157A, X-157B, X-161B, X-171B, X-175C
C147T 7 X-31b, X-113, X-117, X-127, X-135, X-149C6, X-171
G549A 7 X-31b, X-113, X-117, X-127, X-135, X-149C6, X-171
doi:10.1371/journal.pone.0065955.t005
Table 6. HYRs internal genes with recurrent silent changes.
Gene PB2 PB1-F2 PA NP NS1
Position 49 1827 2025 57 1410 210 369 924 144 147 549
PR8[nt] AGA TTC ACA CAA GGG CGG CTC AGA AGT ACC GGG
H1N1 HYRs
X-113 AGA TTC ACA CAG GGG CGG CTC AGA AGT ACT GGA
X-127 CGA TTC ACA CAA GGG CGG CTC AGA AGT ACT GGA
H1N1-SOIV HYRs
X-53 CGA TTC ACA CAA GGA CGG CTC AGA AGC ACC GGG
X-53a CGA TTC ACA CAA GGA CGG CTC AGA AGC ACC GGG
H2N2 HYRs
X-135 CGA TTC ACA CAA GGG CGG CTC AGA AGT ACT GGA
H3N2 HYRs
X-31b CGA TTC ACA CAG GGG CGG CTC AGA AGT ACT GGA
X-117 AGA TTC ACA CAA GGG CGG CTT AGG AGT ACT GGA
X-149C6 AGA TTC ACA CAA GGG CGA CTT AGG AGT ACT GGA
X-157 CGA TTC ACA CAG GGG CGG CTC AGA AGC ACC GGG
X-157A AGA TTT ACG CAA GGG CGG CTC AGA AGC ACC GGG
X-157B AGA TTC ACA CAG GGG CGA CTT AGG AGC ACC GGG
X-161B AGA TTC ACA CAG GGG CGG CTC AGA AGC ACC GGG
X-171 AGA TTC ACA CAA GGG CGG CTC AGA AGT ACT GGA
X-171A AGA TTT ACG CAA GGG CGG CTC AGA AGT ACC GGG
X-171B AGA TTT ACA CAG GGG CGG CTC AGA AGC ACC GGG
X-175C AGA TTC ACA CAG GGG CGG CTC AGA AGC ACC GGG
Recurrent silent changes are given in bold.
doi:10.1371/journal.pone.0065955.t006
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conversions). Three HYRs had a total of nine silent nt changes in
the NP genes (five G-A and four C-T conversions). Among the
HYR genes analyzed, NS1 had the maximum number of silent
changes, 9 C-T, 14 G-A, 8 T-C, 2 A-G and 2 G-C conversions
and NS2 had 7 G-A conversions.
Statistical Analysis
The statistical significance of the recurrent changes was
determined using Student’s ‘t’ test and found the recurrent coding
changes in NS1 (p,0.0331), NS2 (p,0.0012), NP (p,0.026) and
PB1-F2 (p,0.0075) (Table 7) are statistically significant as
compared to the non recurrent coding changes in terms of fold
increase in the HA titer.
HYR Seed Viruses used in Vaccine Production
Out of 23 HYRs analyzed in this study, the mutations found in
9 HYR vaccine seed viruses used in vaccine preparation since X-
31b are given in Table 10 alongside their gene constellation.
Table 7. Recurrent Coding Changes in HYRs.
Protein Change No. of HYRs Recurrent coding changes
PB1 V690I 2 X-161B, X-171B
PB1-F2 C42F 3 X-163, X-163A, X-163B
NP I131M 4 X-163, X-163A, X-163B, X-179A
NS1 E55K 6 X-31b, X-113, X-127, X-135, X-149C6, X-171
NS2 G26E 7 X-31b, X-113, X-117, X-127, X-135, X-149C6, X-171
HA G155E 2 X-53a, X-179
G186V 2 X-171, X-171B
A198deletion 2 X-171, X-171B
K209T 3 X-179, X-179A, PR8xA/KO/68
S219Y 4 X-157, X-157A, X-157B, X-171B
G/D222D 2 X-179, X-179A
Q223R 2 X-179, X-179A
Single letter amino acid code is used.
The recurrent coding changes were found in the ‘internal’ genes of PR8 origin and in the HA genes from the respective wt viruses.
doi:10.1371/journal.pone.0065955.t007
Figure 4. Structural model of H3N2 HA (monomer) with coding
changes found in the H3N2 HYRs in this study. The structure was
generated by PyMOL Molecular Graphics System (www.pymol.org).
Single letter amino acid code is used. The numbers in the parentheses
indicate recurrent changes (see Table 9); underlined changes were
reported earlier [25–27,29,43–45] and also found in our study. 1indicates
unique changes found in the HA1 in this study and 2 indicates unique
changes found in the HA2 region.
doi:10.1371/journal.pone.0065955.g004
Table 8. HYR internal genes with recurrent coding changes.
Proteins PB1 PB1-F2 NP NS1 NS2
nt[aa] 2070(690) 125(42) 393(131) 163(55) 77(26)
PR8 nt[aa] GTA(V) TGC(C) ATA(I) GAG(E) GGG(G)
H1N1
X-113 GTA(V) TGC(C) ATA(I) AAG(K) GAG(E)
X-127 GTA(V) TGC(C) ATA(I) AAG(K) GAG(E)
X-163 GTA(V) TTC(F) ATG(M) GAG(E) GGG(G)
X-163A GTA(V) TTC(F) ATG(M) GAG(E) GGG(G)
X-163B GTA(V) TTC(F) ATG(M) GAG(E) GGG(G)
H1N1-SOIV
X-179A GTA(V) TGC(C) ATG(M) GAG(E) GGG(G)
H2N2
X-135 GTA(V) TGC(C) ATA(I) AAG(K) GAG(E)
H3N2
X-31b GTA(V) TGC(C) ATA(I) AAG(K) GAG(E)
X-117 GTA(V) TGC(C) ATA(I) GAG(E) GAG(E)
X-149C6 GTA(V) TGC(C) ATA(I) AAG(K) GAG(E)
X-161B ATA(I) TGC(C) ATA(I) GAG(E) GGG(G)
X-171 GTA(V) TGC(C) ATA(I) AAG(K) GAG(E)
X-171B ATA(I) TGC(C) ATA(I) GAG(E) GGG(G)
Single letter amino acid code is used.
The recurrent coding changes were found in the ‘internal’ genes of PR8 origin
and are given in bold.
doi:10.1371/journal.pone.0065955.t008
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Discussion
The first inactivated IAV vaccine was produced in chicken eggs
in the 1940s using wt virus. Since clinical isolates grow to low titer
in embryonated chicken eggs, influenza HYRs were developed by
E.D. Kilbourne for use as the ‘seed’ virus for influenza vaccines
and continue to be used for vaccine production to the present. The
hy property of reassortants depends on the natural selection of
variants with mutations favorable to growth. HYRs which derive
PR8 ‘internal’ genes generally grow better than the original wt
virus. However, the egg adaptive changes which occur in the
internal genes of the HYRs are not well defined. Hence, in this
study, the complete genome sequences of 23 HYRs developed
from 14 different wt viruses and the hy donor PR8 were analyzed.
The polymerase complex of influenza virus is comprised of PB2,
PB1 and PA. The PB2 gene is one of the major components of the
replication complex. HYRs with either PR8 or wt PB2 gene
retained a lysine residue at position 627 which has been associated
with host adaptation and virulence [46–50]. It has been
demonstrated that the PB2 gene plays an important role in
regulating host anti-viral response by inhibiting IFN-b production
[51–52]. A large number of silent changes (20) were seen in the
PB2 gene which indicates the importance of adaptation to the egg
host at the RNA level; 11/20 are recurrent changes (Table 5, 6
and Fig. 3). The silent change, A49C was found in six HYRs (X-
31b, X-53, X-53a, X-117, X-127 and X-157) selected for vaccine
production suggesting the possible importance of this nt change to
high growth in ovo. The only coding change in PB2, Pro121Ser,
was found in X-157B and this change may alter secondary
structure.
PB1 plays a key role in cross-species infection and pathogenesis
[49] and was the most frequent internal wt gene segment present
in the HYRs. 12/23 HYRs derived the wt PB1 gene (Fig. 1). Ten
of the 23 HYRs were used in vaccine production and 5/9 had the
wt PB1 genes. The presence of the wt PB1 segment in HYRs used
in vaccines including the CA/2009 PB1 in the HYRs used for the
2009 H1N1pdm production of vaccine must provide a selective
advantage for growth. With regard to HYRs deriving the wt PB1
gene, X-53a had a His576Tyr coding change suggesting that this
coding change may also have contributed to the higher growth of
X-53a in ovo [44]. The 2009 H1N1pdm vaccine seed viruses X-179
and X-179A derived CA/2009 PB1 gene and had no changes,
which suggests the importance of wt PB1 in these reassortants.
Wanitchang and co-workers also reported that a 5:3 reassortant
with CA/2009 PB1 gene had a higher growth rate after
transfection compared to that of 6:2 reassortants with the PR8
PB1 gene [53]. Since the frequency of HYRs deriving wt PB1 gene
is high; comparison of the silent and coding changes found in PR8
and wt derived PB1 may help in understanding the role of
polymerase activity through the PB1 component in terms of viral
growth.
PB1-F2, the second protein encoded in the PB1 gene has been
implicated in pathogenicity [4,54,55] and has been shown to
function in an anti-interferon manner like NS1 [56]. Eleven HYRs
acquired the PB1 gene from PR8; seven of which had the
recurrent silent change A57G in PB1-F2. The X-163 series of
HYRs had a recurrent coding change Cys42Phe in PB1-F2 of the
PB1 protein. The importance of these silent and coding changes in
pathogenicity, including anti-interferon properties and in in ovo
replication, has not been reported.
The PA subunit of the polymerase complex is reported to
induce generalized proteolysis, an activity found in the amino-
terminal third of the PA protein, 247 residues [57,58]. The PA
endonuclease activity is also associated with the amino-terminal
end; the activity resides in the first 209 residues [59]. X-175C with
PR8 derived PA has a coding change, Arg200Cys, in the amino-
terminal region, which may affect the proteolysis and/or
endonuclease activities of PA protein for better growth in ovo.
Other individual coding changes observed in HYRs deriving PA
from PR8, involving residues which may affect the structure and
polarity of the PA protein may allow more efficient interaction
with the other polymerase subunits. Of interest, in three H3N2
HYRs (X-149C6, X-161 and X-171), PA, PB2 and PB1 gene
segments are incorporated from wt viruses. This may permit better
co-operativity of the polymerase subunits for these reassortants.
Conserved regions of IAV polymerase genes critical for efficient
vRNA packaging have been reported to play a role in RNA
structure, RNA-RNA interactions and RNA-protein interactions
[60]. Muramoto and co-workers reported that there is a strong
correlation between the level of PB2 packaged and the levels of
other internal gene vRNAs packaged [61]. In our study, X-157A
(5:3, with wt PB1) and X-171A (4:4 with wt PB1 and NS) had
recurrent silent changes, C1827T and A2025G in the PR8 derived
PB2 genes with no change in the wt derived PB1. X-157A had a
32-fold increase in HA titer whereas X-171A had only a two-fold
increase in HA titer increase compared to their respective wt
viruses [36]. In these cases, in terms of growth, even though both
had the same PB2 mutations, the wt derived NS gene in X-171A
was not associated with enhanced growth as compared with the
PR8 derived NS in X-157A which had one silent and one coding
change. Thus these non-coding changes found in PB2 along with
native PB1 and NS may have resulted in altered viral packaging
thus resulting in differences in their HA titer.
Our analysis of HYRs also showed some correlation between
coding mutations in the polymerase subunits. Although PB2, PB1
and PA interact with each other in a specific manner in controlling
Table 9. HYR hemagglutinins with recurrent coding changes.
Coding Changes at Positionsa
G/D222Db G155E G186V K209T Q223R S219Y A198deletion
X-179 X-53a X-171 X-179 X-179 X-157 X-171
X-179A X-179 X-171B X-179A X-179A X-157A X-171B
PR8xKO/68 X-157B
X-171B
aSingle letter amino acid code used.
bWT parent virus CA/2009 had either G or D; the HYRs had D at position 222.
Amino acid numbering was according to HA subtypes (refer Table 1 for HYR subtype).
doi:10.1371/journal.pone.0065955.t009
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virus replication, the PB1-PA interaction unlike the PB2-PA
interaction, has been well-characterized [17,62-64]. In our study,
HYRs had changes in PB1 and PA regardless of the origin of the
parental genes. The H3N2 HYR, X-175C (used in 2008-09
seasonal vaccine), derived both PB1 and PA from PR8, had
Val344Ile in PB1 and three coding changes Arg200Cys,
Asp302Gly and Lys386Arg in PA. The role of these changes in
efficient interaction of the PB1-PA is not known. X-157B had the
coding changes, Pro121Ser and Val344Ile, in the PR8 derived
PB2 and PA, respectively. The coding change, Pro121Ser will
Table 10. Mutations in influenza A HYR seed viruses used in vaccine preparation.
HYRs Gene Ratio Genes Nucleotide and Amino Acid Changes
H1N1
X-127a 5:3 PB2 A49C
1999-2000 vaccine HA A604G(R202G), A608T(D203V)
NS C147T, G549A; G163A(E55K), G77A(G26E)
H1N1-SOIV
X-53a 5:3 PB2 A49C
1976 Swine PA A1410G
Flu vaccine HA G525A; G457A(E153K), G534A(A178T)
NS T144C
X-53aa 5:3 PB2 A49C
1976 Swine PB1 C1726T(H576Y)
Flu vaccine PA A1410G, G2052T
HA G464A(G155E)
NS T144C
X-179Ab 5:3 HA A626C(K209T), G/D222D, A668G(Q223R)
2009-2013(Present) NP A393G(I131M)
NS G312CA, G338C; A359G, G394A
H3N2
X-31ba 6:2 PB2 A49C
1971-73vaccines HA G1460C(R487T), T1529G(V510G)
NS C147T, G549A; G163A(E55K), G77A(G26E)
X-117a 6:2 PB2 A49C, G1056A, A1953G
1993-94 PB1 G175A(E59K)
vaccine NP C369T, C426T, G924A
NS C147T, G549A; G77A(G26E)
X-157b 6:2/5:3 PB2 A49C
2005-06 PB1c G243T
vaccine PB1d A600G, T675C, T726C, C837T, A861G,
C1902T, G1959A, C1833T, A1869G, T912A,




X-161Bb 6:2 PB1 G2068A(V690I)
2006-08 vaccines NS T144C
X-175Cb 6:2 PB1 G1030A(V344I)





Silent changes are in regular font; Coding changes are in bold font with corresponding aa changes in the parentheses.
aHYRs prepared in E.D. Kilbourne laboratory.
bHYRs prepared in Bucher laboratory at NYMC.
X-157 was a mixture of two populations of HYRs, one with c PR8 PB1 and a second with d NY/04 PB1.
doi:10.1371/journal.pone.0065955.t010
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affect the secondary structure of PB2 while the Val334Ile change is
conservative with the introduction of a slightly longer branched aa
chain in PA. These changes in the structure of PB2 and PA may
help the X-157B viral components interact more efficiently to
improve the viral growth in comparison to its low growing wt
virus.
The NP and its interaction with the polymerase subunits is well
documented. Earlier studies showed that the presence of PR8 NP
was associated with hy phenotype in ovo [30,31,65]. For example,
X-175C had coding changes Lys46Glu and Val344Ile in PR8
derived NP and PB1, respectively. The presence of wt derived NP
with or without mutations in co-operation with either PR8 or wt
derived polymerase subunits in HYR growth must be considered.
For example, PR8xKO/68 and X-171 had coding changes in wt
NP with no change in wt derived PB1 and PB2. Replacement of
the tyrosine with cysteine may affect the NP structure of
PR8xKO/68 with potential formation of an additional disulfide
bond. Introduction of a large basic arginine will increase the
overall charge and hydrophilicity and decrease the flexibility of the
peptide chain of NP for X-171. These coding changes in PR8 or
wt NP suggest they may play a role in efficient interaction with the
polymerase complex for better functioning of the vRNPs.
PR8 M gene is associated with the high growth phenotype in ovo
[31,66–68] and for morphology and progeny particle assembly
[69]. All 23 HYRs derived the M gene from PR8 and no silent or
coding changes were seen. This shows that the highly conserved M
gene of PR8 origin by itself or in combination with other PR8
genes will improve reassortant virus growth. The importance of M
gene in other donor viruses was also demonstrated earlier [68].
However, using WSN virus (not PR8 M gene), Klimov and co-
workers reported that the presence of WSN M in the reassortants
does not guarantee higher growing viruses, because the contribu-
tion of the M can be altered by properties of other genes and the
proteins they encode from the parental viruses [32]. This was true
with the X-161 series of HYRs. The gene constellation of X-161 is
1:7 deriving only the PR8 M gene, and X-161B is a 6:2 HYR
deriving all the internal genes from PR8. In this case, the
difference in the gene constellations plays a key role in determining
growth in ovo, even though few coding changes were found
(Table 4).
The NS gene of influenza virus encodes two distinct proteins,
NS1 [1] and NS2/NEP [70]. NS1 plays a role in virulence [71], is
an interferon antagonist [72–73], enters and accumulates in
infected cells [74] and co-immunoprecipitates with NS1-specific
serum along with the polymerase subunits and NP [75]. With the
exception of the X-163 series and wt derived NS genes, all HYRs
had either a silent or a coding change along with changes in one or
more components of the vRNPs (Table 3 and 4). In NS1, the
recurrent silent change T144C was found in 8; C147T in 7 and
G549A in 7 HYRs (Table 5 and 6). Whereas the recurrent coding
changes Glu55Lys (NS1) and Gly26Glu (NS2) was found in 6 and
7 HYRs, respectively (Table 7 and 8). These changes in NS1 and
NS2 suggest the importance of PR8 derived silent and coding
changes even though the HYRs were developed from wt viruses of
different subtypes. The NS2/NEP protein is involved in nuclear
export of nascent influenza vRNA and regulates viral transcription
and replication [76]. In this analysis we found that the highest
numbers of silent and coding changes were found in the NS gene,
which highlights the importance of variability in the NS gene and
gene products in the enhanced replication of HYRs in ovo.
The essential requirement for HYR vaccine seed candidates is
that both the HA and NA genes must be derived from wt virus. In
the HA, deletion of alanine at position 198 in X-171 and X-171B
was responsible for a more restrictive receptor binding pattern
[29]. Coding changes at positions 153, 155 [43–44], 186, 194 and
219 [29,45], 222, 223 and 226 [25–27,45] were all reported to be
associated with egg adaptation. Both X-179 and X-179A had the
recurrent coding changes, Lys209Thr and Gln223Arg, which were
assumed to be associated with higher growth of these HYRs. The
enhanced growth properties in the X-157 series may be due to the
recurrent coding change Ser219Tyr which has been established as
a residue associated with egg adaptation.
Changes at the antigenic sites have the potential to increase
virus growth and are allowable in HYRs as vaccine seeds as long
as antigenicity is not significantly altered. For example, the H3N2
vaccine component X-175C used in seasonal vaccines in 2008
through 2010 had the coding change Arg142Gly within antigenic
site A with no altered antigenicity. However, changes at residues
153, 154 and 155 within the antigenic site and in the vicinity of
RBS may reduce viral antigenicity [43,44,77]. HYRs that have
changes at these residues may be excluded as vaccine candidates,
even though these changes may improve virus growth. For
example, even though a Gly155Glu mutation was associated with
significant fold increase in HA titer over the wt virus, there was
altered antigenicity in a CA/2009 reassortant candidate developed
by Chen and co-workers for the live attenuated vaccine which
made them unsuitable as vaccine candidates [28]. This Gly155Glu
mutation was also seen in X-53a [44] and in X-179 [78]. X-179
with high growth properties had been considered a strong
candidate ‘seed’ for H1N1pdm vaccine; however the Gly155Glu
mutation altered the antigenicity and was not acceptable for use in
the 2009 H1N1pdm vaccine. On the other hand, Gly186Val was
reported to improve the growth of CA/2009 [28], A/Fujian/411/
2002 [45] and A/Singapore/21/04 [79] without affecting
antigenicity. Widjaja et al. [45] reported that adaptation of A/
Fujian/411/2002 in ovo was due to the coding change Gly186Val,
at aa position 186. At CSL, Ltd., a series of genetically modified
reassortants based on the X-179A sequence data were developed
[80] and were found to have improved in ovo growth, which further
implicates the importance of these residues Lys209Thr and
Gln223Arg in virus adaptation and growth. In comparison to X-
179A, another H1N1pdm seed virus, X-181 had an additional
coding change, Asn129Asp, which may have contributed to the
higher growth of X-181 as compared with X-179A [78].
Coding changes were found in the HA2 region of the HA genes
of H2N2 and H3N2 HYRs which were not previously reported
and are unique to this study. These changes are found in the
amino terminus region of the HA2 protein of X-135 (Lys401Asn),
X-31b (Arg487Thr and Val510Gly) and X-171A (Asp489Asn).
Although the number of changes are fewer than seen for HA1, it is
interesting to note that three of four changes in HA2 involve loss of
charged aa residues (aspartic acid, lysine and arginine) which will
lead to a reduction in overall protein charge. As the amino
terminus region of HA2 is involved in virus entry [40], the role of
these residues in egg adaptation should be studied further.
The NA of influenza virus is a homotetramer and functions in
the release of progeny virus from the infected host cell [81–83]. It
has been reported that functional balance of HA and NA regulates
the efficiency of virus replication [84]. Similar to HA, NA is also
under evolutionary pressure from serum antibodies existing in the
population [85]. In this study, only two H3N2 HYRs showed
coding changes in the NA, Thr31Ala in X-171A and Thr32Ile in
X-175C. Both coding changes were found in the hydrophobic
NH2 terminus of NA, which is inserted in the membrane [86].
These changes may facilitate growth in ovo. No changes are seen at
the active site of the NA in contrast to the many changes seen in
the RBS in HA. Evidently, wt NA is well-suited to replicate in ovo
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or readily accommodates the changes in HA for optimal viral
replication.
The importance of silent mutations on virus replication and
evolution has been shown [87–92]. Silent mutations in RNA
viruses may be far from neutral and can contribute significantly to
host adaptation and become fixed in the viral RNA quasi-species
populations during genetic drift [93–96]. A recurring silent
change, A49C in PB2 and A57G in PB1-F2 are assumed to be
primarily derived from PR8 variants which are positively selected
by the egg host. Wong and co workers showed that silent changes
in PB2 affect replication and adaptation [97]; as also seen in the
present study where 20 out of 21 changes in the PB2 gene were
silent. Selection pressures acting against the use of G or C at the
third codon position [98] and primarily C to T mutation bias in
human influenza viral genomes has been reported [17,97,99].
Reduced GC content in influenza viruses may prevent the
activation of the human innate immune system thereby allowing
more efficient viral RNA translation [100]. In this study, the in ovo
prepared HYRs also showed a majority of replacement of third
codon G and C by A and T, thereby reducing the overall GC
content.
Influenza viruses undergo Darwinian selection resulting in
mutants that efficiently replicate in ovo. When two distinct
influenza viruses replicate in embryonated chicken eggs the
interactions between the virus and the host cell proteins are
crucial for virus replication, assembly and trafficking [101]. A
crucial aspect to the vaccine manufacturing process is to obtain a
reassortant with high growth in ovo, thus providing the maximal
amount of virus for preparation of the inactivated vaccine. The
gene constellation differences (PR8:wt genes) are equally impor-
tant for the high growth phenotype exhibited by the HYRs in ovo.
Apart from the gene composition, based on the analysis of the
HYRs, we hypothesize that in addition to the recurrent mutations,
the individual changes found in all eight genes and their encoded
proteins of HYRs prepared as candidate seed viruses may
augment growth by playing important roles in in ovo virus
replication. Hence, further identification of mutations in addition-
al HYRs as they are developed may help in the design of high
growth seed viruses with improved growth in ovo.
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